Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial

Antonio Ruggiero; Cesare Colosimo; Giuseppe Barone; Vita Ridola; Riccardo Riccardi; Graziella Cefalo; Maura Massimino; Filippo Spreafico; Paolo Potepan; Massimo E. Abate; Maurizio Mascarin; Maria Luisa Garrè; Giorgio Perilongo; Enrico Madon

doi:10.1093/neuonc/not320

Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial

Antonio Ruggiero, Cesare Colosimo, Giuseppe Barone, Vita Ridola, Riccardo Riccardi, Graziella Cefalo, Maura Massimino, Filippo Spreafico, Paolo Potepan, Massimo E. Abate, Maurizio Mascarin, Maria Luisa Garrè, Giorgio Perilongo, Enrico Madon

Risultato della ricerca: Contributo in rivista › Articolo in rivista

35 Citazioni (Scopus)

Abstract

The aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ). The secondary purpose was to analyze the toxicity profile of TMZ when administered orally for 5 days in 3 divided daily doses every 28 days.

Lingua originale	English
pagine (da-a)	748-753
Numero di pagine	6
Rivista	Neuro-Oncology
Volume	16
DOI	https://doi.org/10.1093/neuonc/not320
Stato di pubblicazione	Pubblicato - 2014

Keywords

medulloblastoma
phase II trial
temozolomide

Accesso al documento

10.1093/neuonc/not320

Altri file e collegamenti

Link a IRIS PubliCatt

Fingerprint Entra nei temi di ricerca di 'Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial'. Insieme formano una fingerprint unica.

Cita questo

Ruggiero, A., Colosimo, C., Barone, G., Ridola, V., Riccardi, R., Cefalo, G., Massimino, M., Spreafico, F., Potepan, P., Abate, M. E., Mascarin, M., Garrè, M. L., Perilongo, G., & Madon, E. (2014). Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial. Neuro-Oncology, 16, 748-753. https://doi.org/10.1093/neuonc/not320

Ruggiero, Antonio ; Colosimo, Cesare ; Barone, Giuseppe ; Ridola, Vita ; Riccardi, Riccardo ; Cefalo, Graziella ; Massimino, Maura ; Spreafico, Filippo ; Potepan, Paolo ; Abate, Massimo E. ; Mascarin, Maurizio ; Garrè, Maria Luisa ; Perilongo, Giorgio ; Madon, Enrico. / Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial. In: Neuro-Oncology. 2014 ; Vol. 16. pagg. 748-753.

@article{aa7414d8497e47dab95b813169aa1462,

title = "Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial",

abstract = "The aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ). The secondary purpose was to analyze the toxicity profile of TMZ when administered orally for 5 days in 3 divided daily doses every 28 days.",

keywords = "medulloblastoma, phase II trial, temozolomide, medulloblastoma, phase II trial, temozolomide",

author = "Antonio Ruggiero and Cesare Colosimo and Giuseppe Barone and Vita Ridola and Riccardo Riccardi and Graziella Cefalo and Maura Massimino and Filippo Spreafico and Paolo Potepan and Abate, {Massimo E.} and Maurizio Mascarin and Garr{\`e}, {Maria Luisa} and Giorgio Perilongo and Enrico Madon",

year = "2014",

doi = "10.1093/neuonc/not320",

language = "English",

volume = "16",

pages = "748--753",

journal = "Neuro-Oncology",

issn = "1522-8517",

publisher = "Carden Jennings Pub.",

}

Ruggiero, A , Colosimo, C, Barone, G, Ridola, V, Riccardi, R, Cefalo, G, Massimino, M, Spreafico, F, Potepan, P, Abate, ME, Mascarin, M, Garrè, ML, Perilongo, G & Madon, E 2014, 'Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial', Neuro-Oncology, vol. 16, pagg. 748-753. https://doi.org/10.1093/neuonc/not320

Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial. / Ruggiero, Antonio ; Colosimo, Cesare; Barone, Giuseppe; Ridola, Vita; Riccardi, Riccardo; Cefalo, Graziella; Massimino, Maura; Spreafico, Filippo; Potepan, Paolo; Abate, Massimo E.; Mascarin, Maurizio; Garrè, Maria Luisa; Perilongo, Giorgio; Madon, Enrico.

In: Neuro-Oncology, Vol. 16, 2014, pag. 748-753.

Risultato della ricerca: Contributo in rivista › Articolo in rivista

TY - JOUR

T1 - Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial

AU - Ruggiero, Antonio

AU - Colosimo, Cesare

AU - Barone, Giuseppe

AU - Ridola, Vita

AU - Riccardi, Riccardo

AU - Cefalo, Graziella

AU - Massimino, Maura

AU - Spreafico, Filippo

AU - Potepan, Paolo

AU - Abate, Massimo E.

AU - Mascarin, Maurizio

AU - Garrè, Maria Luisa

AU - Perilongo, Giorgio

AU - Madon, Enrico

PY - 2014

Y1 - 2014

N2 - The aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ). The secondary purpose was to analyze the toxicity profile of TMZ when administered orally for 5 days in 3 divided daily doses every 28 days.

AB - The aim of this study was to assess the objective response rate (ORR) of children and young adults with recurrent medulloblastoma/primitive neuroectodermal tumor (MB/PNET) treated with temozolomide (TMZ). The secondary purpose was to analyze the toxicity profile of TMZ when administered orally for 5 days in 3 divided daily doses every 28 days.

KW - medulloblastoma

KW - phase II trial

KW - temozolomide

KW - medulloblastoma

KW - phase II trial

KW - temozolomide

UR - http://hdl.handle.net/10807/55974

U2 - 10.1093/neuonc/not320

DO - 10.1093/neuonc/not320

M3 - Article

VL - 16

SP - 748

EP - 753

JO - Neuro-Oncology

JF - Neuro-Oncology

SN - 1522-8517

ER -